chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Sex: U
Vaccine: COVID19, COVID19
Symptoms: COVID-19 immunisation, Interchange of vaccine products, No adverse event
Clinical narrative: First was biontech and then i got the Moderna for second; First was biontech and then i got the Moderna for second; No adverse event; This spontaneous case was reported by a consumer and describes the occurrence of COVID-19 IMMUNISATION (First was biontech and then i got the Moderna for second), INTERCHANGE OF VACCINE PRODUCTS (First was biontech and then i got the Moderna for second) and NO ADVERSE EVENT (No adverse event) in a  patient of an unknown age and gender who received mRNA-1273 (Spikevax) for COVID-19 prophylaxis.    Co-suspect product included non-company product TOZINAMERAN (PFIZER BIONTECH COVID-19 VACCINE) for an unknown indication.    No Medical History information was reported.   On an unknown date, the patient received second dose of mRNA-1273 (Spikevax) (unknown route) 1 dosage form and first dose of TOZINAMERAN (PFIZER BIONTECH COVID-19 VACCINE) (unknown route) 1 dosage form. On an unknown date, the patient experienced COVID-19 IMMUNISATION (First was biontech and then i got the Moderna for second), INTERCHANGE OF VACCINE PRODUCTS (First was biontech and then i got the Moderna for second) and NO ADVERSE EVENT (No adverse event). At the time of the report, COVID-19 IMMUNISATION (First was biontech and then i got the Moderna for second), INTERCHANGE OF VACCINE PRODUCTS (First was biontech and then i got the Moderna for second) and NO ADVERSE EVENT (No adverse event) outcome was unknown.            Concomitant medications were not reported.  No treatment information was provided by the reporter.  This case was identified as part of a retrospective clean-up activity where certain emails received in the Moderna mailbox were missed to be booked-in.
Age: 66.0
Sex: F
Vaccine: COVID19
Symptoms: COVID-19, SARS-CoV-2 test
Clinical narrative: COVID-19; This spontaneous case was reported by a consumer and describes the occurrence of COVID-19 (COVID-19) in a 66-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.    Co-suspect product included non-company product ADALIMUMAB (HUMIRA) for Rheumatoid arthritis.    No Medical History information was reported.   On 02-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 02-Mar-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 02-Sep-2021, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On an unknown date, the patient started ADALIMUMAB (HUMIRA) (Subcutaneous) at an unspecified dose. On an unknown date, the patient experienced COVID-19 (COVID-19). At the time of the report, COVID-19 (COVID-19) was resolving.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, SARS-CoV-2 test: (Positive) Positive.         No concomitant medication provided. No treatment information mentioned.  On an unknown date, patient experienced COVID.  This case was identified as part of a retrospective clean-up activity where certain emails received in the Moderna mailbox were missed to be booked-in  Company comment: This spontaneous case concerns a 66-years-old female patient, with medical history of Rheumatoid arthritis treated with ADALIMUMAB (HUMIRA), who experienced the unexpected non serious AESI of COVID-19, that occurred in context to a dose with mRNA-1273 vaccine. SARS-CoV-2 test was Positive as on unspecified date. No further information on risk factors, co morbidities and treatment was available in the report. The event outcome was resolving. Non-company product ADALIMUMAB (HUMIRA) for Rheumatoid arthritis could be the risk factor for the event. Ongoing COVID-19 pandemic could be confounding for the event. The benefit-risk relationship of mRNA-1273 is not affected by this report. Events seriousness was assessed as per medical judgement and available information.; Sender's Comments: This spontaneous case concerns a 66-years-old female patient, with medical history of Rheumatoid arthritis treated with ADALIMUMAB (HUMIRA), who experienced the unexpected non serious AESI of COVID-19, that occurred in context to a dose with mRNA-1273 vaccine. SARS-CoV-2 test was Positive as on unspecified date. No further information on risk factors, co morbidities and treatment was available in the report. The event outcome was resolving. Non-company product ADALIMUMAB (HUMIRA) for Rheumatoid arthritis could be the risk factor for the event. Ongoing COVID-19 pandemic could be confounding for the event. The benefit-risk relationship of mRNA-1273 is not affected by this report. Events seriousness was assessed as per medical judgement and available information.
Age: 35.0
Sex: F
Vaccine: COVID19
Symptoms: Psoriasis, Vaccination site pain
Clinical narrative: SORE ARM FOLLOWING COVID VACCINE; PSORIASIS FLARE; This spontaneous case was reported by a consumer and describes the occurrence of PSORIASIS (PSORIASIS FLARE) and VACCINATION SITE PAIN (SORE ARM FOLLOWING COVID VACCINE) in a 35-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.    Co-suspect product included non-company product ADALIMUMAB (HUMIRA) for Plaque psoriasis.    Concurrent medical conditions included Plaque psoriasis (Moderate to severe).   In November 2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient started ADALIMUMAB (HUMIRA) (Subcutaneous) Citrate free. In October 2021, the patient experienced PSORIASIS (PSORIASIS FLARE). In November 2021, the patient experienced VACCINATION SITE PAIN (SORE ARM FOLLOWING COVID VACCINE). At the time of the report, PSORIASIS (PSORIASIS FLARE) and VACCINATION SITE PAIN (SORE ARM FOLLOWING COVID VACCINE) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       This case was identified as part of a retrospective clean-up activity where certain emails received in the Moderna mailbox were missed to be booked-in.  Concomitant medications were not reported.  It was unknown if patient was enrolled in a covid-19 vaccine trial. Treatment medications were not reported.  The reporter's causality for the event(s) of SORE ARM FOLLOWING COVID VACCINE and PSORIASIS FLARE with respect to Humira was not provided.
Age: 46.0
Sex: F
Vaccine: COVID19
Symptoms: Blood pressure measurement, Dysmenorrhoea, Hypertension
Clinical narrative: Menstrual cramps; Blood pressure high; This spontaneous case was reported by a consumer and describes the occurrence of DYSMENORRHOEA (Menstrual cramps) and HYPERTENSION (Blood pressure high) in a 46-year-old female patient who received mRNA-1273 (Spikevax) for COVID-19 vaccination.    Co-suspect product included non-company product ELAGOLIX SODIUM, ESTRADIOL, NORETHISTERONE ACETATE (ORIAHNN) for Uterine fibroids.    Concurrent medical conditions included Uterine fibroids.   On 01-May-2022, the patient started ELAGOLIX SODIUM, ESTRADIOL, NORETHISTERONE ACETATE (ORIAHNN) (Oral) Unknown. On an unknown date, the patient received dose of mRNA-1273 (Spikevax) (Intramuscular) 1 dosage form. In May 2022, the patient experienced DYSMENORRHOEA (Menstrual cramps) and HYPERTENSION (Blood pressure high). At the time of the report, DYSMENORRHOEA (Menstrual cramps) and HYPERTENSION (Blood pressure high) had not resolved.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, Blood pressure measurement: High.     The action taken with mRNA-1273 (Spikevax) (Intramuscular) was unknown.       No concomitant medications were reported.  In 01-May-2022, the patient began ORIAHNN, upon taking medication, she stopped experiencing menstrual spotting. She continued to experienced menstrual cramps. She concurrently had high blood pressure, since receiving COVID immunization and was currently on high blood pressure medication (unspecified). She did not give consent to be contacted.  It was unknown if patient was enrolled in a COVID-19 vaccine trial.  Primary reporter contact for lot number information was unsuccessful.  The reporter's causality for the event of dysmenorrhea was a reasonable possibility and the reporter's causality for the event of hypertension was no reasonable possibility with ORIAHNN (ELAGOLIX).  This case was identified as part of a retrospective clean-up activity where certain emails received in the Moderna mailbox were missed to be booked-in.
Age: 65.0
Sex: M
Vaccine: COVID19
Symptoms: Headache, Hypoacusis, Pain in extremity
Clinical narrative: Hard of hearing; Pain in arm/ Sore arm; Headache; This spontaneous case was reported by a consumer and describes the occurrence of HYPOACUSIS (Hard of hearing), PAIN IN EXTREMITY (Pain in arm/ Sore arm) and HEADACHE (Headache) in a 65-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.    Co-suspect product included non-company product ADALIMUMAB (HUMIRA) injection for Panuveitis.    Concurrent medical conditions included Panuveitis.   On 22-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 09-Feb-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. In 2022, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On an unknown date, the patient started ADALIMUMAB (HUMIRA) (Subcutaneous) Citrate free. In 2021, the patient experienced PAIN IN EXTREMITY (Pain in arm/ Sore arm) and HEADACHE (Headache). On an unknown date, the patient experienced HYPOACUSIS (Hard of hearing). At the time of the report, HYPOACUSIS (Hard of hearing), PAIN IN EXTREMITY (Pain in arm/ Sore arm) and HEADACHE (Headache) outcome was unknown.            Concomitant products were not provided. Treatment medication was not reported.  It was unknown if patient was enrolled in a COVID-19 Vaccine Trial.  This case was identified as part of a retrospective clean-up activity where certain emails received in the Moderna mailbox were missed to be booked-in.
Sex: M
Vaccine: COVID19
Symptoms: COVID-19, SARS-CoV-2 test
Clinical narrative: COVID-19; This spontaneous case was reported by a consumer and describes the occurrence of COVID-19 (COVID-19) in an adult male patient who received mRNA-1273 (Spikevax) for COVID-19 vaccination.    Co-suspect product included non-company product ADALIMUMAB (HUMIRA) solution for injection for Psoriatic arthritis.    Concurrent medical conditions included Psoriatic arthritis.   On an unknown date, the patient received dose of mRNA-1273 (Spikevax) (Intramuscular) 1 dosage form and ADALIMUMAB (HUMIRA) (Subcutaneous) at an unspecified dose. On an unknown date, the patient experienced COVID-19 (COVID-19). At the time of the report, COVID-19 (COVID-19) had resolved.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, SARS-CoV-2 test: (Positive) Positive.     The action taken with mRNA-1273 (Spikevax) (Intramuscular) was unknown.       No concomitant product was reported. No treatment information was reported. It was unknown if patient was enrolled in a COVID-19 vaccine trial. The reporter's causality for the event with Humira was no reasonable possibility. This case was identified as part of a retrospective clean-up activity where certain emails received in the Moderna mailbox were missed to be booked-in.  Company comment  This is a spontaneous case reported by a consumer, concerning an adult male patient of unknown age, with no medical history reported, who experienced the unexpected, non serious AESI event of COVID 19 with a positive SARS-CoV-2 test, unknown  days after receiving a dose of mRNA-1273 Vaccine in the covid 19 vaccination series. Concurrent medical conditions included Psoriatic arthritis. On an unknown date the patient was started on ADALIMUMAB (HUMIRA) (Subcutaneous) injection at an unspecified dose for Psoriatic Arthritis. Details of risk factors, other co morbidities, clinical course, concomitant medications and treatment details were not reported. The outcome of covid 19 was resolved. Ongoing Covid 19 pandemia, and use of Adalimumab could be considered as confounder to the events. The benefit-risk relationship of mRNA-1273 vaccine is not affected by this report.; Sender's Comments: This is a spontaneous case reported by a consumer, concerning an adult male patient of unknown age, with no medical history reported, who experienced the unexpected, non serious AESI event of COVID 19 with a positive SARS-CoV-2 test, unknown  days after receiving a dose of mRNA-1273 Vaccine in the covid 19 vaccination series. Concurrent medical conditions included Psoriatic arthritis. On an unknown date the patient was started on ADALIMUMAB (HUMIRA) (Subcutaneous) injection at an unspecified dose for Psoriatic Arthritis. Details of risk factors, other co morbidities, clinical course, concomitant medications and treatment details were not reported. The outcome of covid 19 was resolved. Ongoing Covid 19 pandemia, and use of Adalimumab could be considered as confounder to the events. The benefit-risk relationship of mRNA-1273 vaccine is not affected by this report.
Sex: F
Vaccine: COVID19
Symptoms: Hypersensitivity, Malaise, Musculoskeletal stiffness, Pain, Pain in extremity
Clinical narrative: Feeling sick; Stiffness; FELT BODY ACHE; Allergies; Pain in arm; This spontaneous case was reported by a consumer and describes the occurrence of MALAISE (Feeling sick), MUSCULOSKELETAL STIFFNESS (Stiffness), PAIN (FELT BODY ACHE), HYPERSENSITIVITY (Allergies) and PAIN IN EXTREMITY (Pain in arm) in an adult female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.    Co-suspect product included non-company product ADALIMUMAB (HUMIRA) for Rheumatoid arthritis.    Previously administered products included for COVID-19 vaccination: PFIZER BIONTECH COVID-19 VACCINE (Route: Intramuscular Dose 1) on 01-Jan-2021 and Pfizer/BioNTech COVID-19 vaccine (Route: Intramuscular Dose 2) on 05-Feb-2021. Past adverse reactions to the above products included No adverse event with PFIZER BIONTECH COVID-19 VACCINE and Pfizer/BioNTech COVID-19 vaccine.   On 30-Nov-2021, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient started ADALIMUMAB (HUMIRA) (Subcutaneous) at an unspecified dose. On an unknown date, the patient experienced MALAISE (Feeling sick), MUSCULOSKELETAL STIFFNESS (Stiffness), PAIN (FELT BODY ACHE), HYPERSENSITIVITY (Allergies) and PAIN IN EXTREMITY (Pain in arm). At the time of the report, MALAISE (Feeling sick), HYPERSENSITIVITY (Allergies) and PAIN IN EXTREMITY (Pain in arm) had resolved and MUSCULOSKELETAL STIFFNESS (Stiffness) and PAIN (FELT BODY ACHE) had not resolved. Not Provided          Concomitant product use was not provided by the reporter.  The patient received third booster dose of Moderna vaccine. On unknown dates, the patient experienced feeling sick, stiffness, allergies, arm pain and felt body ache. No treatment information was provided. This case was identified as part of a retrospective clean-up activity where certain emails received in the Moderna mailbox were missed to be booked-in.   Reporter did not allow further contact
Sex: F
Vaccine: COVID19
Symptoms: Arthralgia, Fatigue, Headache, Myalgia, Vaccination site pain
Clinical narrative: SWOLLEN ARM FROM MODERNA VACCINE; Fatigue; SORE ARM FROM MODERNA; MORE JOINT PAIN/FLARE UP OF JOINT PAIN; PAIN IN HAMSTRING FLARE UP; Headache; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE SWELLING (SWOLLEN ARM FROM MODERNA VACCINE), FATIGUE (Fatigue), VACCINATION SITE PAIN (SORE ARM FROM MODERNA), ARTHRALGIA (MORE JOINT PAIN/FLARE UP OF JOINT PAIN) and MYALGIA (PAIN IN HAMSTRING FLARE UP) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.    Co-suspect product included non-company product ADALIMUMAB (HUMIRA) for Psoriatic arthritis.    Concurrent medical conditions included Psoriatic arthritis.   On 12-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 12-Mar-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 15-Sep-2021, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On an unknown date, the patient started ADALIMUMAB (HUMIRA) (Subcutaneous) Citrate Free. On an unknown date, the patient experienced VACCINATION SITE SWELLING (SWOLLEN ARM FROM MODERNA VACCINE), FATIGUE (Fatigue), VACCINATION SITE PAIN (SORE ARM FROM MODERNA), ARTHRALGIA (MORE JOINT PAIN/FLARE UP OF JOINT PAIN), MYALGIA (PAIN IN HAMSTRING FLARE UP) and HEADACHE (Headache). At the time of the report, VACCINATION SITE SWELLING (SWOLLEN ARM FROM MODERNA VACCINE), FATIGUE (Fatigue), VACCINATION SITE PAIN (SORE ARM FROM MODERNA), MYALGIA (PAIN IN HAMSTRING FLARE UP) and HEADACHE (Headache) outcome was unknown and ARTHRALGIA (MORE JOINT PAIN/FLARE UP OF JOINT PAIN) had not resolved.            No information on concomitant medication were reported. It was unknown if patient was enrolled in a COVID-19 Vaccine Trial. Causality for HUMIRA(ADALIMUMAB): The reporter's causality for the event(s) of SWOLLEN ARM FROM MODERNA VACCINE, FATIGUE, SORE ARM FROM MODERNA VACCINE and HEADACHE with HUMIRA(ADALIMUMAB) was no reasonable possibility. The reporter's causality for the event(s) of PAIN IN HAMSTRING FLARE UP and MORE JOINT PAIN/FLARE UP OF JOINT PAIN with HUMIRA(ADALIMUMAB) was a reasonable possibility. No treatment details were reported. This case was identified as part of a retrospective clean-up activity where certain emails received in the Moderna mailbox were missed to be booked-in.
Sex: F
Vaccine: COVID19
Symptoms: Vaccination site swelling
Clinical narrative: SWOLLEN ARM FROM MODERNA VACCINE; Fatigue; SORE ARM FROM MODERNA; MORE JOINT PAIN/FLARE UP OF JOINT PAIN; PAIN IN HAMSTRING FLARE UP; Headache; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE SWELLING (SWOLLEN ARM FROM MODERNA VACCINE), FATIGUE (Fatigue), VACCINATION SITE PAIN (SORE ARM FROM MODERNA), ARTHRALGIA (MORE JOINT PAIN/FLARE UP OF JOINT PAIN) and MYALGIA (PAIN IN HAMSTRING FLARE UP) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.    Co-suspect product included non-company product ADALIMUMAB (HUMIRA) for Psoriatic arthritis.    Concurrent medical conditions included Psoriatic arthritis.   On 12-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 12-Mar-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 15-Sep-2021, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On an unknown date, the patient started ADALIMUMAB (HUMIRA) (Subcutaneous) Citrate Free. On an unknown date, the patient experienced VACCINATION SITE SWELLING (SWOLLEN ARM FROM MODERNA VACCINE), FATIGUE (Fatigue), VACCINATION SITE PAIN (SORE ARM FROM MODERNA), ARTHRALGIA (MORE JOINT PAIN/FLARE UP OF JOINT PAIN), MYALGIA (PAIN IN HAMSTRING FLARE UP) and HEADACHE (Headache). At the time of the report, VACCINATION SITE SWELLING (SWOLLEN ARM FROM MODERNA VACCINE), FATIGUE (Fatigue), VACCINATION SITE PAIN (SORE ARM FROM MODERNA), MYALGIA (PAIN IN HAMSTRING FLARE UP) and HEADACHE (Headache) outcome was unknown and ARTHRALGIA (MORE JOINT PAIN/FLARE UP OF JOINT PAIN) had not resolved.            No information on concomitant medication were reported. It was unknown if patient was enrolled in a COVID-19 Vaccine Trial. Causality for HUMIRA(ADALIMUMAB): The reporter's causality for the event(s) of SWOLLEN ARM FROM MODERNA VACCINE, FATIGUE, SORE ARM FROM MODERNA VACCINE and HEADACHE with HUMIRA(ADALIMUMAB) was no reasonable possibility. The reporter's causality for the event(s) of PAIN IN HAMSTRING FLARE UP and MORE JOINT PAIN/FLARE UP OF JOINT PAIN with HUMIRA(ADALIMUMAB) was a reasonable possibility. No treatment details were reported. This case was identified as part of a retrospective clean-up activity where certain emails received in the Moderna mailbox were missed to be booked-in.
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Pain in extremity
Clinical narrative: First 3 Pfizer and 4 th Moderna. Mildly sore arm; This spontaneous case was reported by a consumer and describes the occurrence of PAIN IN EXTREMITY (First 3 Pfizer and 4 th Moderna. Mildly sore arm) in a male patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 prophylaxis.    Co-suspect product included non-company product TOZINAMERAN (PFIZER BIONTECH COVID-19 VACCINE) for an unknown indication.    No Medical History information was reported.   On an unknown date, the patient received fourth dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form and first dose of TOZINAMERAN (PFIZER BIONTECH COVID-19 VACCINE) (unknown route) 1 dosage form. On an unknown date, received second dose of TOZINAMERAN (PFIZER BIONTECH COVID-19 VACCINE) (unknown route) dosage was changed to 1 dosage form and third dose of TOZINAMERAN (PFIZER BIONTECH COVID-19 VACCINE) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced PAIN IN EXTREMITY (First 3 Pfizer and 4 th Moderna. Mildly sore arm). At the time of the report, PAIN IN EXTREMITY (First 3 Pfizer and 4 th Moderna. Mildly sore arm) outcome was unknown.            No concomitant medications were reported. No treatment medications were reported. This case was identified as part of a retrospective clean-up activity where certain emails received in the Moderna mailbox were missed to be booked-in.
Age: 79.0
Sex: F
Vaccine: COVID19
Symptoms: Pain
Clinical narrative: Pain; This spontaneous case was reported by a consumer and describes the occurrence of PAIN (Pain) in a 79-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.    Co-suspect product included non-company product ADALIMUMAB (HUMIRA) solution for injection for Rheumatoid arthritis.    Concurrent medical conditions included Rheumatoid arthritis.   On 31-Jan-2022, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient started ADALIMUMAB (HUMIRA) (Subcutaneous) Citrate Free, UNK. In 2022, the patient experienced PAIN (Pain). In 2022, PAIN (Pain) had resolved.            No concomitant product was reported. No treatment information was reported. It was unknown if patient was enrolled in a COVID-19 vaccine trial. The reporter's causality for the event with Humira was a reasonable possibility. This case was identified as part of a retrospective clean-up activity where certain emails received in the Moderna mailbox were missed to be booked-in.   This case was linked to MOD-2022-621085 (Patient Link).
Age: 82.0
Sex: F
Vaccine: COVID19
Symptoms: Headache, Inappropriate schedule of product administration, Migraine
Clinical narrative: migraines; first shot of the Pfizer Covid 19 vaccine and got the moderna shot for her second shot; Headache; This spontaneous case was reported by a patient family member or friend and describes the occurrence of MIGRAINE (migraines), INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (first shot of the Pfizer Covid 19 vaccine and got the moderna shot for her second shot) and HEADACHE (Headache) in an 82-year-old female patient who received mRNA-1273 (Spikevax) for COVID-19 prophylaxis.     No Medical History information was reported.    On an unknown date, the patient received second dose of mRNA-1273 (Spikevax) (unknown route) 1 dosage form. On an unknown date, the patient experienced MIGRAINE (migraines), INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (first shot of the Pfizer Covid 19 vaccine and got the moderna shot for her second shot) and HEADACHE (Headache). At the time of the report, MIGRAINE (migraines), INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (first shot of the Pfizer Covid 19 vaccine and got the moderna shot for her second shot) and HEADACHE (Headache) outcome was unknown.            No Concomitant medications were reported. No treatment medications were reported.  This case was identified as part of a retrospective clean-up activity where certain emails received in the Moderna mailbox were missed to be booked-in.   Reporter did not allow further contact
Sex: M
Vaccine: COVID19
Symptoms: Psoriasis
Clinical narrative: Psoriasis aggravated; This spontaneous case was reported by a consumer and describes the occurrence of PSORIASIS (Psoriasis aggravated) in an adult male patient who received mRNA-1273 (Spikevax) for COVID-19 vaccination.    Co-suspect product included non-company product ADALIMUMAB (HUMIRA) for Psoriasis.    Concurrent medical conditions included Psoriasis (Moderate to severe chronic plaque psoriasis).   On an unknown date, the patient received dose of mRNA-1273 (Spikevax) (Intramuscular) 1 dosage form and ADALIMUMAB (HUMIRA) (Subcutaneous) UNK, Citrate Free. On an unknown date, the patient experienced PSORIASIS (Psoriasis aggravated). At the time of the report, PSORIASIS (Psoriasis aggravated) outcome was unknown.        The action taken with mRNA-1273 (Spikevax) (Intramuscular) was unknown.       There was no reported medical history.  Concomitant medications details were not reported.  It was reported that plaque psoriasis was coming back slowly for the patient.  It was unknown if patient was enrolled in a COVID-19 Vaccine Trial.   The reporter's causality for the event of psoriasis aggravated was not provided for Humira.  No treatment information was reported.  This case was identified as part of a retrospective clean-up activity where certain emails received in the moderna mailbox were missed to be booked-in.
Age: 80.0
Sex: F
Vaccine: COVID19
Symptoms: Nasopharyngitis, Vaccination site pain
Clinical narrative: Cold; Vaccination site pain; This spontaneous case was reported by a consumer and describes the occurrence of NASOPHARYNGITIS (Cold) and VACCINATION SITE PAIN (Vaccination site pain) in an 80-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.    Co-suspect product included non-company product ADALIMUMAB (HUMIRA) for Crohn's disease.    No Medical History information was reported.   On 25-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 22-Feb-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 28-Oct-2021, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On an unknown date, the patient started ADALIMUMAB (HUMIRA) (Subcutaneous) at an unspecified dose. In 2021, the patient experienced VACCINATION SITE PAIN (Vaccination site pain). On an unknown date, the patient experienced NASOPHARYNGITIS (Cold). At the time of the report, NASOPHARYNGITIS (Cold) was resolving and VACCINATION SITE PAIN (Vaccination site pain) had resolved.            No concomitant medications was reported. No treatment medications was reported.  It was unknown if patient was enrolled in a COVID-19 vaccine trial.  This case was identified as part of a retrospective clean-up activity where certain emails received in the Moderna mailbox were missed to be booked-in.
Age: 46.0
Sex: M
Vaccine: COVID19
Symptoms: Nasopharyngitis, Psoriasis, SARS-CoV-2 test, Vaccination site pain
Clinical narrative: Plaque psoriasis small spots came back; Sore arm after second COVID-19 Moderna shot; Cold; This spontaneous case was reported by a patient and describes the occurrence of NASOPHARYNGITIS (Cold), PSORIASIS (Plaque psoriasis small spots came back) and VACCINATION SITE PAIN (Sore arm after second COVID-19 Moderna shot) in a 46-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.    Co-suspect product included non-company product RISANKIZUMAB (SKYRIZI [RISANKIZUMAB]) for Plaque psoriasis.    No Medical History information was reported.   On 15-Jul-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 25-Aug-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On an unknown date, the patient started RISANKIZUMAB (SKYRIZI [RISANKIZUMAB]) (Subcutaneous) at an unspecified dose. In August 2021, the patient experienced NASOPHARYNGITIS (Cold). On 25-Aug-2021, the patient experienced VACCINATION SITE PAIN (Sore arm after second COVID-19 Moderna shot). In September 2021, the patient experienced PSORIASIS (Plaque psoriasis small spots came back). On 26-Aug-2021, VACCINATION SITE PAIN (Sore arm after second COVID-19 Moderna shot) had resolved. At the time of the report, NASOPHARYNGITIS (Cold) had not resolved and PSORIASIS (Plaque psoriasis small spots came back) had resolved.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, SARS-CoV-2 test: (Negative) Negative.         No concomitant medications were provided. No treatment information was provided.  This case was identified as part of a retrospective clean-up activity where certain emails received in the Moderna mailbox were missed to be booked-in.
Age: 61.0
Sex: F
Vaccine: COVID19
Symptoms: Vaccination site pain
Clinical narrative: Sore arm with first COVID vaccine; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE PAIN (Sore arm with first COVID vaccine) in a 61-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination. Co-suspect product included non-company product ADALIMUMAB (HUMIRA) for Rheumatoid arthritis. Concurrent medical conditions included Rheumatoid arthritis (Moderate to severe rheumatoid arthritis). On 19-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient started ADALIMUMAB (HUMIRA) (Subcutaneous) 1 dosage form. On an unknown date, ADALIMUMAB (HUMIRA) (Subcutaneous) dosage was changed to 1 dosage form. In 2021, the patient experienced VACCINATION SITE PAIN (Sore arm with first COVID vaccine). At the time of the report, VACCINATION SITE PAIN (Sore arm with first COVID vaccine) outcome was unknown. mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosing remained unchanged. No concomitant medication was reported. No treatment medication was reported. It was unknown if patient was enrolled in a COVID-19 vaccine trial. The reporter's causality for the event of sore arm with first COVID vaccine was not provided for Humira. This case was identified as part of a retrospective clean-up activity where certain emails received in the Moderna mailbox were missed to be booked-in. This case was linked to MOD-2022-629995 (Patient Link).
Age: 56.0
Sex: F
Vaccine: COVID19
Symptoms: Back pain, Blister, Cardiac function test
Clinical narrative: Pain in lower back; BLISTERS ON HAND AND FEET; This spontaneous case was reported by a consumer and describes the occurrence of BACK PAIN (Pain in lower back) and BLISTER (BLISTERS ON HAND AND FEET) in a 56-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.    Co-suspect product included non-company product ADALIMUMAB (HUMIRA) for Psoriatic arthritis.    No known allergies.  Concurrent medical conditions included Psoriatic arthritis.   On 30-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 27-Apr-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 18-Apr-2022, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On an unknown date, the patient started ADALIMUMAB (HUMIRA) (Subcutaneous) at an unspecified dose. On an unknown date, ADALIMUMAB (HUMIRA) (Subcutaneous) dosage was changed to at an unspecified dose. In April 2022, the patient experienced BACK PAIN (Pain in lower back) and BLISTER (BLISTERS ON HAND AND FEET). At the time of the report, BACK PAIN (Pain in lower back) outcome was unknown and BLISTER (BLISTERS ON HAND AND FEET) was resolving.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, Cardiac function test: Heart levels were a little elevated.         Concomitant product use was not provided by the reporter.  On an unknown date, the patient experienced heart test results/ heart levels were a little elevated. In Apr-2022, the patient ended up with blisters on hand and feet and pain in lower back after taking booster dose of Moderna covid-19 vaccine. No treatment information was provided. The reporter's causality of Humira for the event(s) took covid booster vaccine/ended up with blisters on hand and feet, took covid booster vaccine/ended up with pain in lower back was no reasonable possibility. This case was identified as part of a retrospective clean-up activity where certain emails received in the Moderna mailbox were missed to be booked-in.   Reporter did not allow further contact   Most recent FOLLOW-UP information incorporated above includes: On 29-Jul-2022: Live follow up added and it contains lab data added, event outcome updated, causality updated for the reporter and narrative updated.
Sex: M
Vaccine: COVID19
Symptoms: Furuncle, Headache, Musculoskeletal stiffness, Neck pain, Oropharyngeal pain
Clinical narrative: Boils on right butt, cheek, under nipples and on legs; Hand burns; Neck pain; Throat pain; spine pain; stiffness behind head, neck, throat and spine; Left arm tingles down to the hand; Head pain; This spontaneous case was reported by a patient and describes the occurrence of FURUNCLE (Boils on right butt, cheek, under nipples and on legs), SKIN BURNING SENSATION (Hand burns), NECK PAIN (Neck pain), OROPHARYNGEAL PAIN (Throat pain) and SPINAL PAIN (spine pain) in an adult male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.    Co-suspect product included non-company product ADALIMUMAB (HUMIRA) for Ankylosing spondylitis.    Concurrent medical conditions included Ankylosing spondylitis.   On 01-Oct-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient started ADALIMUMAB (HUMIRA) (Subcutaneous) Citrate Free. On an unknown date, the patient experienced FURUNCLE (Boils on right butt, cheek, under nipples and on legs), SKIN BURNING SENSATION (Hand burns), NECK PAIN (Neck pain), OROPHARYNGEAL PAIN (Throat pain), SPINAL PAIN (spine pain), MUSCULOSKELETAL STIFFNESS (stiffness behind head, neck, throat and spine), PARAESTHESIA (Left arm tingles down to the hand) and HEADACHE (Head pain). At the time of the report, FURUNCLE (Boils on right butt, cheek, under nipples and on legs), SKIN BURNING SENSATION (Hand burns), NECK PAIN (Neck pain), OROPHARYNGEAL PAIN (Throat pain), SPINAL PAIN (spine pain), MUSCULOSKELETAL STIFFNESS (stiffness behind head, neck, throat and spine), PARAESTHESIA (Left arm tingles down to the hand) and HEADACHE (Head pain) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant medications were reported.  It was unknown if patient was enrolled in a COVID-19 Vaccine Trial.  No treatment medications were reported.  The reporter's causality for the events of head pain, left arm tingles down to the hand, boils on right butt cheek, under nipples and on legs, hand burns, neck pain, throat pain, spine pain and stiffness behind head, neck, throat and spine was not provided with HUMIRA(ADALIMUMAB).  This case was identified as part of a retrospective clean-up activity where certain emails received in the Moderna mailbox were missed to be booked-in.   This case was linked to MOD-2022-630553 (Patient Link).
Sex: M
Vaccine: COVID19
Symptoms: Paraesthesia, Skin burning sensation, Spinal pain
Clinical narrative: Boils on right butt, cheek, under nipples and on legs; Hand burns; Neck pain; Throat pain; spine pain; stiffness behind head, neck, throat and spine; Left arm tingles down to the hand; Head pain; This spontaneous case was reported by a patient and describes the occurrence of FURUNCLE (Boils on right butt, cheek, under nipples and on legs), SKIN BURNING SENSATION (Hand burns), NECK PAIN (Neck pain), OROPHARYNGEAL PAIN (Throat pain) and SPINAL PAIN (spine pain) in an adult male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.    Co-suspect product included non-company product ADALIMUMAB (HUMIRA) for Ankylosing spondylitis.    Concurrent medical conditions included Ankylosing spondylitis.   On 01-Oct-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient started ADALIMUMAB (HUMIRA) (Subcutaneous) Citrate Free. On an unknown date, the patient experienced FURUNCLE (Boils on right butt, cheek, under nipples and on legs), SKIN BURNING SENSATION (Hand burns), NECK PAIN (Neck pain), OROPHARYNGEAL PAIN (Throat pain), SPINAL PAIN (spine pain), MUSCULOSKELETAL STIFFNESS (stiffness behind head, neck, throat and spine), PARAESTHESIA (Left arm tingles down to the hand) and HEADACHE (Head pain). At the time of the report, FURUNCLE (Boils on right butt, cheek, under nipples and on legs), SKIN BURNING SENSATION (Hand burns), NECK PAIN (Neck pain), OROPHARYNGEAL PAIN (Throat pain), SPINAL PAIN (spine pain), MUSCULOSKELETAL STIFFNESS (stiffness behind head, neck, throat and spine), PARAESTHESIA (Left arm tingles down to the hand) and HEADACHE (Head pain) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant medications were reported.  It was unknown if patient was enrolled in a COVID-19 Vaccine Trial.  No treatment medications were reported.  The reporter's causality for the events of head pain, left arm tingles down to the hand, boils on right butt cheek, under nipples and on legs, hand burns, neck pain, throat pain, spine pain and stiffness behind head, neck, throat and spine was not provided with HUMIRA(ADALIMUMAB).  This case was identified as part of a retrospective clean-up activity where certain emails received in the Moderna mailbox were missed to be booked-in.   This case was linked to MOD-2022-630553 (Patient Link).
Age: 50.0
Sex: F
Vaccine: COVID19
Symptoms: Headache, Insomnia, Myalgia, Nausea
Clinical narrative: Sleeplessness; Nausea; Body aches; Headache; This spontaneous case was reported by a patient and describes the occurrence of INSOMNIA (Sleeplessness), NAUSEA (Nausea), MYALGIA (Body aches) and HEADACHE (Headache) in a 50-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.    Co-suspect product included non-company product ADALIMUMAB (HUMIRA) for Rheumatoid arthritis.    Concurrent medical conditions included Rheumatoid arthritis (Moderate to severe).   On 16-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 14-May-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 23-Feb-2022, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On an unknown date, the patient started ADALIMUMAB (HUMIRA) (Subcutaneous) Citrate free. On 23-Feb-2022, the patient experienced INSOMNIA (Sleeplessness), NAUSEA (Nausea), MYALGIA (Body aches) and HEADACHE (Headache). At the time of the report, INSOMNIA (Sleeplessness), NAUSEA (Nausea), MYALGIA (Body aches) and HEADACHE (Headache) had not resolved.            No concomitant medications were reported.  The reporter causality for the events of sleeplessness, body aches, headache and nausea with Humira (adalimumab) was no reasonable possibility.  It was unknown if patient was enrolled in a COVID-19 Vaccine Trial.  No treatment medications were reported.  This case was identified as part of a retrospective clean-up activity where certain emails received in the Moderna mailbox were missed to be booked-in.
Sex: M
Vaccine: COVID19
Symptoms: Allergic cough, Arthralgia, Back pain, Pruritus
Clinical narrative: Pruritus aggravated/ excessive itching all over body; Allergic cough/ cough from allergies; Back pain; Wrist pain; This spontaneous case was reported by a patient and describes the occurrence of PRURITUS (Pruritus aggravated/ excessive itching all over body), ALLERGIC COUGH (Allergic cough/ cough from allergies), BACK PAIN (Back pain) and ARTHRALGIA (Wrist pain) in an elderly male patient who received mRNA-1273 (Spikevax) for COVID-19 vaccination.    Co-suspect product included non-company product ADALIMUMAB (HUMIRA) for Rheumatoid arthritis.    Concurrent medical conditions included Rheumatoid arthritis (Moderate to severe).   On an unknown date, the patient received dose of mRNA-1273 (Spikevax) (Intramuscular) 1 dosage form and ADALIMUMAB (HUMIRA) (Subcutaneous) Citrate free. On an unknown date, the patient experienced PRURITUS (Pruritus aggravated/ excessive itching all over body), ALLERGIC COUGH (Allergic cough/ cough from allergies), BACK PAIN (Back pain) and ARTHRALGIA (Wrist pain). At the time of the report, PRURITUS (Pruritus aggravated/ excessive itching all over body) had resolved and ALLERGIC COUGH (Allergic cough/ cough from allergies), BACK PAIN (Back pain) and ARTHRALGIA (Wrist pain) was resolving.        The action taken with mRNA-1273 (Spikevax) (Intramuscular) was unknown.       No concomitant medications were reported.  It was unknown if patient was enrolled in a COVID-19 Vaccine Trial.  The reporter causality for the events of cough from allergies, excessive itching all over body, back pain and wrist pain with Humira (adalimumab) was no reasonable possibility.   No treatment medications were reported.  This case was identified as part of a retrospective clean-up activity where certain emails received in the Moderna mailbox were missed to be booked-in.
Age: 57.0
Sex: M
Vaccine: COVID19
Symptoms: Cough, Inappropriate schedule of product administration, Vaccination site pain
Clinical narrative: Dry cough; Second dose received 24-JUN-2021/Booster received 27-JUL-2021; Left arm sore after receiving covid booster; This spontaneous case was reported by a consumer and describes the occurrence of COUGH (Dry cough), VACCINATION SITE PAIN (Left arm sore after receiving covid booster) and INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Second dose received 24-JUN-2021/Booster received 27-JUL-2021) in a 57-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.    Co-suspect product included non-company product ADALIMUMAB (HUMIRA) solution for injection for Plaque psoriasis and Psoriatic arthritis.    Concurrent medical conditions included Psoriatic arthritis and Plaque psoriasis.   On 24-May-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 24-Jun-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 27-Jul-2021, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On an unknown date, the patient started ADALIMUMAB (HUMIRA) (Subcutaneous) Solution for injection in pre-filled pen. In 2021, the patient experienced VACCINATION SITE PAIN (Left arm sore after receiving covid booster). On an unknown date, the patient experienced COUGH (Dry cough) and INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Second dose received 24-JUN-2021/Booster received 27-JUL-2021). At the time of the report, COUGH (Dry cough), VACCINATION SITE PAIN (Left arm sore after receiving covid booster) and INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Second dose received 24-JUN-2021/Booster received 27-JUL-2021) outcome was unknown.            The concomitant medication was not reported by reporter It was unknown if patient was enrolled in a COVID-19 Vaccine Trial. The treatment medication was not reported by reporter. On an unknown date patient had a CAT scan and results not reported.  This case was identified as part of a retrospective clean-up activity where certain emails received in the Moderna mailbox were missed to be booked-in.
Sex: U
Vaccine: COVID19
Symptoms: Chills
Clinical narrative: Shivers; This spontaneous case was reported by a consumer and describes the occurrence of CHILLS (Shivers) in a  patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 prophylaxis.     Previously administered products included for Product used for unknown indication: PFIZER BIONTECH COVID-19 VACCINE (Dose 2) and PFIZER BIONTECH COVID-19 VACCINE (Dose 1). Past adverse reactions to the above products included No adverse event with PFIZER BIONTECH COVID-19 VACCINE and PFIZER BIONTECH COVID-19 VACCINE.    On an unknown date, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced CHILLS (Shivers). At the time of the report, CHILLS (Shivers) had resolved.            No concomitant medications were reported.  The patient had shivers for a whole day.  No treatment details were reported.  I-narrartive: This case was identified as part of a retrospective clean-up activity where certain emails received in the Moderna mailbox were missed to be booked-in.   Most recent FOLLOW-UP information incorporated above includes: On 23-Mar-2022: Follow-up document included no new information.
Sex: M
Vaccine: COVID19
Symptoms: Taste disorder
Clinical narrative: Its wierd ass flavour of it; This spontaneous case was reported by a patient and describes the occurrence of TASTE DISORDER (Its wierd ass flavour of it) in a male patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 prophylaxis.     No Medical History information was reported.   On an unknown date, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form and first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced TASTE DISORDER (Its wierd ass flavour of it). At the time of the report, TASTE DISORDER (Its wierd ass flavour of it) outcome was unknown. Not Provided          No concomitant medications was reported. The patient pretty much have the same symptoms as his wife, but all tests have been negative. No treatment medications was reported.  This case was identified as part of a retrospective clean-up activity where certain emails received in the Moderna mailbox were missed to be booked-in.